A brand new analysis paper was printed in Oncotarget’s Quantity 14 on June 12, 2023, entitled, “LP-284, a small molecule acylfulvene, exerts potent antitumor exercise in preclinical non-Hodgkin’s lymphoma fashions and in cells poor in DNA injury restore.”
Regardless of advances in therapies treating non-Hodgkin’s lymphoma (NHL), 20~40% of sufferers expertise relapsed or refractory illness. Whereas stable tumors with homologous recombination deficiencies have been efficiently focused with artificial deadly brokers corresponding to poly-ADP ribose polymerase (PARP) inhibitors, such artificial lethality technique has not but been accepted to deal with sufferers with NHL.
On this new research, researchers Jianli Zhou, Drew Sturtevant, Cassie Love, Aditya Kulkarni, Neha Biyani, Umesh Kathad, Elizabeth Thacker, Sandeep Dave, and Kishor Bhatia from Lantern Pharma Inc., Duke College and Information Pushed Bioscience investigated the mechanism of motion (MoA) and therapeutic potential of a new-generation acylfulvene compound, LP-284, in each in vitro and in vivo NHL fashions.
“Right here, we aimed to characterize LP-284’s antitumor efficacy in NHL fashions and additional elucidate its mechanisms of motion.”
Considered one of LP-284’s MoA contains inducing the restore of double-strand DNA break (DSB). The researchers discovered that LP-284 exerts nanomolar efficiency in a panel of hematological most cancers cell strains together with fifteen NHL cell strains. In vivo, LP-284 therapy prolongs the survival of mantle cell lymphoma (MCL) cell line JeKo-1 derived xenograft mice by two-fold and reveals elevated efficacy over bortezomib and ibrutinib.
As well as, LP-284 is able to inhibiting tumor progress of JeKo-1 xenografts which are refractory to bortezomib or ibrutinib. They additional confirmed that LP-284 is especially deadly in cells with poor DNA injury response and restore, a targetable vulnerability in NHL.
“In conclusion, our research has demonstrated LP-284 as a novel and potent acylfulvene drug that may suppress tumor progress in NHL fashions and cells with HR or TC-NER deficiency.”
Supply:
Journal reference:
Zhou, J., et al. (2023) LP-284, a small molecule acylfulvene, exerts potent antitumor exercise in preclinical non-Hodgkin’s lymphoma fashions and in cells poor in DNA injury restore. Oncotarget. doi.org/10.18632/oncotarget.28454.
